Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Chapman

Showing results (921-930 of 1,011) with videos related to

Pageof 102
Sort By:
The New England Journal of Medicine|May 19, 2006
Volume progression in polycystic kidney diseaseJared J Grantham, Vicente E Torres, Arlene B Chapman, et al.
JCI Insight|July 8, 2020
The value of genotypic and imaging information to predict functional and structural outcomes in ADPKDSravanthi Lavu, Lisa E Vaughan, Sarah R Senum, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney diseaseVicente E Torres, Bernard F King, Arlene B Chapman, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohortKyongtae T Bae, Fang Zhu, Arlene B Chapman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 8, 2018
Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD TrialsGodela M Brosnahan, Kaleab Z Abebe, Charity G Moore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2015
Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective studyL Beltrame, M Di Marino, R Fruscio, et al.
Lancet (London, England)|June 28, 2012
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Jean-Jacques Grob, Lev V Demidov, et al.
The New England Journal of Medicine|November 18, 2014
Angiotensin blockade in late autosomal dominant polycystic kidney diseaseVicente E Torres, Kaleab Z Abebe, Arlene B Chapman, et al.
Journal of Neurotrauma|June 8, 2011
Recommendations for the use of common outcome measures in pediatric traumatic brain injury researchStephen R McCauley, Elisabeth A Wilde, Vicki A Anderson, et al.
The Lancet. Oncology|October 12, 2012
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialGeorgina V Long, Uwe Trefzer, Michael A Davies, et al.
Pageof 102

Showing results (921-930 of 1,011) with videos related to

Sort By:
Pageof 102
The New England Journal of Medicine|May 19, 2006
Volume progression in polycystic kidney diseaseJared J Grantham, Vicente E Torres, Arlene B Chapman, et al.
JCI Insight|July 8, 2020
The value of genotypic and imaging information to predict functional and structural outcomes in ADPKDSravanthi Lavu, Lisa E Vaughan, Sarah R Senum, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney diseaseVicente E Torres, Bernard F King, Arlene B Chapman, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohortKyongtae T Bae, Fang Zhu, Arlene B Chapman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 8, 2018
Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD TrialsGodela M Brosnahan, Kaleab Z Abebe, Charity G Moore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2015
Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective studyL Beltrame, M Di Marino, R Fruscio, et al.
Lancet (London, England)|June 28, 2012
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Jean-Jacques Grob, Lev V Demidov, et al.
The New England Journal of Medicine|November 18, 2014
Angiotensin blockade in late autosomal dominant polycystic kidney diseaseVicente E Torres, Kaleab Z Abebe, Arlene B Chapman, et al.
Journal of Neurotrauma|June 8, 2011
Recommendations for the use of common outcome measures in pediatric traumatic brain injury researchStephen R McCauley, Elisabeth A Wilde, Vicki A Anderson, et al.
The Lancet. Oncology|October 12, 2012
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialGeorgina V Long, Uwe Trefzer, Michael A Davies, et al.
Pageof 102